PRIMER // WHAT IS KLOW
What Is KLOW Peptide? A Plain-English Overview
Four peptides. One research vial. A plain-English reading of what each component is, what each component's studies found, and what no study has tested.
The plain-English answer
What is KLOW peptide? It is a research blend: four separate peptides dissolved together in one laboratory vial. The four are KPV, GHK-Cu, BPC-157 and TB-500. Together they weigh 80 mg in the most common research-vial configuration — 50 mg of GHK-Cu, 10 mg each of BPC-157, TB-500 and KPV.
None of the four is a single common molecule like a vitamin or a steroid. Each is a short chain of amino acids — the same building blocks as protein — engineered into a sequence studied for a specific biological effect. KPV is three amino acids long and studied for calming inflammation. GHK-Cu is three amino acids plus a copper ion, studied for skin repair and gene modulation. BPC-157 is fifteen amino acids, with a large record in rodent tissue-repair studies. TB-500 is seven amino acids, a fragment of a larger protein involved in cell migration.
The blend itself has never been tested. No laboratory has ever asked whether mixing these four into one vial changes what they do. Every claim about the combination is extrapolated from single-component experiments. That is the honest starting point for reading everything else on this board.
KLOW peptide blend — the four components
The KLOW peptide blend is a co-formulation, not a chemical entity. The four components remain separate molecules in the vial; they do not react to form a new compound. Each has its own CAS number, molecular weight and research lineage.
KPV (Lys-Pro-Val; CAS 67727-97-3; MW 342.44 Da): The C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Anti-inflammatory mechanism: inhibits NF-kappaB (the master transcription switch for inflammatory gene expression) and MAPK signaling. Taken up into inflamed gut cells via the PepT1 transporter. Reduced colitis severity in mice [3].
GHK-Cu (Gly-His-Lys copper complex; CAS 89030-95-5; MW 402.92 Da): Naturally occurring in human plasma, declining with age. Modulates the expression of approximately 31.2% of human genes in the direction of matrix repair, antioxidant defense and DNA fidelity [5]. Increased collagen in 70% of women in topical clinical studies [4]. Supplies copper for the enzyme that crosslinks collagen.
BPC-157 (15-mer; CAS 137525-51-0; MW 1419.53 Da): Derived from a gastric-juice protein. Drives new blood vessel formation via the VEGFR2 pathway. Accelerated Achilles tendon healing in rats [2]. A 2025 IV safety pilot found it well tolerated at 20 mg in two adults [6].
TB-500 (Ac-LKKTETQ; MW 889.02 Da): A fragment of thymosin beta-4, a 43-amino-acid protein. Carries the LKKTET actin-binding motif that sequesters monomeric actin, linked to cell migration. Full-length thymosin beta-4 increased wound re-epithelialization by 42% at 4 days in rats [1]. The TB-500 fragment's equivalence to the full protein is not established.
Regulatory status — read with the blend
None of the four components is FDA-approved for human systemic use. GHK-Cu has approved cosmetic topical applications. BPC-157 is in FDA category 2 of the 503A bulk-substances compounding review. TB-500 and KPV have no approved human formulation.
The WADA consideration: thymosin beta-4 — the parent protein of TB-500 — is on the WADA Prohibited List under S2 (peptide hormones and growth factors), banned at all times. Athletes subject to anti-doping testing should treat KLOW as off-limits. See the full caution on the KLOW effects page.
None of the four is a weight-loss or GLP-1-related compound. The blend is a recovery and repair research formulation, distinct from metabolic or incretin peptides.
What has been studied versus what has not
The component research record is real and worth reading. Thymosin beta-4 data go back to 1999 and include a Phase 1 IV tolerability study in 40 healthy adults [9]. BPC-157 rodent tissue-repair studies number in the dozens; human data are limited to small pilots. GHK-Cu has the most human evidence — topical cosmetic trials — and the broadest transcriptome data [4][5]. KPV has cell-culture and murine colitis data [3].
What has not been studied: the four-peptide KLOW blend as a combination. No in-vitro co-culture. No rodent model. No human trial. Every synergy claim is a mechanistic extrapolation from these four separate single-component records.
KLOW vs GLOW — the key structural difference
GLOW is a separate three-peptide blend — GHK-Cu, BPC-157 and TB-500 — that lacks the KPV component. KLOW adds KPV as the fourth arm, expanding the blend into the anti-inflammatory / gut-mucosa node. The two blends share three components but differ in the inclusion of the KPV anti-inflammatory tripeptide. Community accounts frequently describe KLOW as feeling more anti-inflammatory than GLOW, attributing the difference to KPV; this is a community observation, not a head-to-head study.